Compare Abeona Therapeutics Inc (ABEO) vs ProShares Ultra QQQ ETF (QLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs ProShares Ultra QQQ ETF — how do they compare? Abeona Therapeutics Inc trades at $7.57 (market cap $421.19M), while ProShares Ultra QQQ ETF trades at $92.15. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, ProShares Ultra QQQ ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | QLD | |
|---|---|---|
Market Cap | $421.19M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $7.45 | $100.53 |
52-Week Low | $4.17 | $57.16 |
Enterprise Value | $276.10M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
QLD, the ProShares Ultra QQQ ETF, trades at $92.2, up 2.3% today, reflecting strong bullish momentum. Technical indicators show a bullish moving average consensus and key support at $91, with resistance at $93. Recent institutional buying, including a 29.4% stake increase by 180 Wealth Advisors in Q2 2026, underscores confidence. The ETF has delivered over 10,000% total return since inception, though its leveraged structure amplifies volatility.
The outlook for QLD is cautiously optimistic, driven by tech sector strength and tactical ETF demand. However, risks include amplified losses during market downturns, with a historical maximum drawdown of 63.80%. Investors should weigh the potential for outsized gains against the inherent volatility of daily leveraged products in a shifting economic landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →
